Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204


Cancer Therapy Through Control of Cell Migration

Volume:5   Issue:7
Pp: 505-518
Eugene G. Levin
DOI: 10.2174/156800905774574048

Inhibition of Angiogenesis by Cleaved High Molecular Weight Kininogen (HKa) and HKa Domain 5

Volume:5   Issue:7
Pp: 519-528
Keith R. McCrae, Fernando Donate, Sergei Merkulov, Danyu Sun, Xiaoping Qi and David E. Shaw
DOI: 10.2174/156800905774574039

Anti-Angiogenic and Anti-Tumor Properties of Proteasome Inhibitors

Volume:5   Issue:7
Pp: 529-541
Kenyon G. Daniel, Deborah J. Kuhn, Aslamuzzaman Kazi and Q. P. Dou
DOI: 10.2174/156800905774574075

Control of Copper Status for Cancer Therapy

Volume:5   Issue:7
Pp: 543-549
Vicki L. Goodman, George J. Brewer and Sofia D. Merajver
DOI: 10.2174/156800905774574066

Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose

Volume:5   Issue:7
Pp: 551-559
Yuval Shaked, Guido Bocci, Raquel Munoz, Shan Man, John M.L. Ebos, Daniel J. Hicklin, Francesco Bertolini, Robert D'Amato and Robert S. Kerbel
DOI: 10.2174/156800905774574020